docetaxel anhydrous has been researched along with orantinib in 4 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 110 | 19 | 36 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | orantinib (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 2.186 | |
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | 3.6 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 1.126 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 3.003 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.028 | |
| Platelet-derived growth factor receptor alpha | Mus musculus (house mouse) | 3.6 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 1.8986 | |
| Aurora kinase B | Homo sapiens (human) | 0.041 | |
| Aurora kinase C | Homo sapiens (human) | 0.21 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aogi, K; Arioka, H; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Sato, Y; Takatsuka, Y; Toi, M; Tokuda, Y | 1 |
| Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Park, HS; Ro, J; Song, HS; Yoo, C | 2 |
| Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kim, J; Kim, SB; Lee, KS; Park, HS; Ro, J; Sohn, BS; Song, HS | 1 |
2 trial(s) available for docetaxel anhydrous and orantinib
| Article | Year |
|---|---|
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Indoles; Middle Aged; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Indoles; Middle Aged; Oxindoles; Propionates; Pyrroles; Taxoids | 2014 |
2 other study(ies) available for docetaxel anhydrous and orantinib
| Article | Year |
|---|---|
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; C-Reactive Protein; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factors; Humans; Indoles; Interleukin-6; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Taxoids; Vascular Endothelial Growth Factor A | 2016 |
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Quality of Life; Taxoids | 2017 |